Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C14H15BrClNO6
CAS Number:
Molecular Weight:
408.63
NACRES:
NA.83
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
230-640-8
MDL number:
Beilstein/REAXYS Number:
1402009
Product Name
5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside, ≥98%
assay
≥98%
form
powder
solubility
DMF: methanol (1:1): soluble 50 mg/mL
suitability
suitable for identification of lac+ bacterial colonies
storage temp.
−20°C
SMILES string
OC[C@H]1O[C@@H](Oc2c[nH]c3ccc(Br)c(Cl)c23)[C@H](O)[C@@H](O)[C@H]1O
InChI
1S/C14H15BrClNO6/c15-5-1-2-6-9(10(5)16)7(3-17-6)22-14-13(21)12(20)11(19)8(4-18)23-14/h1-3,8,11-14,17-21H,4H2/t8-,11+,12+,13-,14-/m1/s1
InChI key
OPIFSICVWOWJMJ-AEOCFKNESA-N
Application
X-Gal is a chromogenic substrate for β-galactosidase that produces a rich blue color that can easily be detected visually over background. X-Gal is the substrate of choice for blue-white selection of recombinant bacterial colonies with the lac+ genotype.
5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside has been used to confirm transduction of Caki-2/LacZ clones. It has also been used in blue-white selection of transformants.
Preparation Note
A stock solution (100 mg/ml) is prepared by dissolving X-Gal in dimethylformamide and should be stored at −20 °C and protected from light. Sterilization is not required.
Still not finding the right product?
Explore all of our products under 5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
HSV-tk gene therapy for human renal cell carcinoma in nude mice
Pulkkanen K, et al.
Cancer Gene Therapy, 8(7), 529-529 (2001)
Rolling circle amplification to screen yam germplasm for badnavirus infections and to amplify and characterise novel badnavirus genomes
Bomer M, et al.
Bio-protocol, 8(1), 529-529 (2018)
Yibing Wang et al.
PloS one, 8(3), e59195-e59195 (2013-03-26)
Our study had three objectives: to extend the plasmid-based transformation protocol to a clinical isolate of C. trachomatis belonging to the trachoma biovar, to provide "proof of principle" that it is possible to "knock out" selected plasmid genes (retaining a